Liposomales Doxorubicin

Zusammenfassung

In der neoadjuvanten, adjuvanten und metastasierten Therapie des Mammakarzinoms sind Anthrazykline bis heute ein essentieller Bestandteil. Liposomal enkapsuliertes Doxorubicin (LED) zeigt bei gleicher Effektivität weniger Kardiotoxizität im Vergleich zu herkömmlichen Anthrazyklinen. Die therapeutische Reserve wird bei metastasiertem Brust-krebs durch verminderte Toxizität von LED erweitert, selbst wenn bereits vorher Anthrazy-kline verwendet wurden. Auf dem diesjährigen ASCO stand in mehreren Studien die Effektivität und Toxizität von liposomalem Doxorubicin auf dem Prüfstand. Insbesondere in der neoadjuvanten Therapie könnte die Substanz einen zukünftigen Standard darstellen, auch in Kombination mit anderen, potentiell kardiotoxischen Substanzen, z.B. Trastuzumab.

Summary

Anthracylines are an essentiell part in the current therapy of breast cancer. Liposomal encapsulated doxorubicin (LED) compared to common anthracyclines has a similar effectivity but less cardiotoxicity. The therapeutic reserve in advanced breast cancer ist enlarged by LED even when anthracyclines were used before. On the ASCO meeting this year effectivity and toxicity of liposomal doxorubicin were proved. Particularly in the neoadjuvant setting this substance alone or in combination with potential cardiotoxic substances, such as trastuzumab, could develop to a new standard cytotoxic therapy.

Schlüsselwörter

Liposomales Doxorubicin - Kardiotoxizität - Frühes Mammakarzinom - Metastasiertes Mammakarzinom

Keywords

Liposomal doxorubicin - cardiotoxicity - early breast cancer - metastatic breast cancer

• Literatur

• 1 Diagnostik und Therapie von Patientinnen mit primärem und metastasierten Brustkrebs. AGO e. V., Guidelines Breast Version 2013.1 D. Available from: URL: http://ago-online.de
• 2 Amadori D, Milandri C, Comella G, Saracchini S, Salvagni S, Barone C. et al. A phase I/II trial of nonpegylated liposomal doxorubicin, docetaxel, and trastuzumab as first-line treastment in HER-2-positive locally advanced or metastatic breast cancer. Eur J Cancer 2011; 47: 2091-2098.
• 3 Batist G, Pamakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T. et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophophamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
• 4 Brown S, Khan DR. The Treatment of Breast Cancer Using Liposome Technology. J Drug Deliv 2012. Article ID 212965. Available from: URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312267/?report=reader
• 5 Brunner C, Jaeger T, Suppan C, Mueller-Holzner E, Jasarevic Z, Balic M. et al. Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel and trastuzumab as neoadjuvant therapy In HER2-overexpressing breast cancer: A restrospective analysis. ASCO 2013. J Clin Oncol 2013 31. (suppl; abstr 583). Available at: URL: http://meetinglibrary.asco.org/content/116353-132
• 6 Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: Should we abandon anthracyclines?. J Clin Oncol 2012; 18: 2179-2182.
• 7 Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P. et al. Nonpegylated Liposomal Doxoruvicxin (TLC-D99), Paclitaxel, an Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. Clin Cancer Res 2009; 15 (01) 307-314.
• 8 De La Pena L, Cortes J, Manikhas A, Roman L, Semiglazov V, Biakhov MY. et al. Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC). ASCO 2013. J Clinical Oncol 2013; 31 (suppl; abstr 517)
• 9 Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for deliverey of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691-743.
• 10 Gao J, Zhong W, He J, Li H, Zhang H, Zhou G. et al. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int J Pharm 2009; 374: 145-152.
• 11 HemOnc Today, July 10, 2009. Available at: URL: http://www.healio.com/hematology-oncology/breast-cancer/news/print/hematology-oncology/%7Bbccf5629-277b-4591-b4d1-65320a4063e9%7D/phasing-out-anthracyclines-in-breast-cancer-is-it-time“
• 12 Jones S, Holmes FA, O´Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ. et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 2009; 27: 1178-1183.
• 13 Lao J, Madani J, Puértolas T, Alvarez M, Hernandez A, Pazo-Cid R. et al. Liposomal doxorubicin in the treatment of breast cancer patients: A review. J Drug Deliv 2013. Available at: URL: http://dx.doi.org/10.1155/2013/456409
• 14 Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-284.
• 15 Palival SR, Paliwai R, Mishra N, Mehta A, Vyas SP. A novel cancer targeting approach based on estrone anchored stealth liposomefor site-specific breast cander therapy. Curr Cancer Drug Targets 2010; 10: 343-353.
• 16 Ryberg M, Nielsen D, Cortese G, Nielsen G, skovsgaard T, Anderesen PK. New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients. J Natl Cancer Ins 2008; 100: 1058-1067.
• 17 Saracchini S, Foltran L, Tuccia F, Bassini A, Sulfaro S, Micheli E. et al. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. Breast 2013, Sep 26. S0960-9776(13)00250-6 [Epub ahead of print]
• 18 Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A. et al. Use of chemotherapy plus a monchlonal antibody against HER2 for metastatic breast cancer that overexpressees HER2. N Engl J Med 2001; 344: 783-792.
• 19 Slamon DJ, Eiermann W, Robert N, Pienkowski T, Martin M, Press M. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
• 20 Speyer JL, Green MD, Zleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J. et al. ICRF-1887 perits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-127.
• 21 Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. A retrospective analysis of three trials. Cancer 2003; 11: 2869-2879.
• 22 Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer 2009; 2: 101-107.
• 23 Untch M. et al. Cardiac safety of trastuzumab in combination weith epirubcin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. European Journal of Cancer 2004; 40: 988-997.
• 24 Venturini M, Bighin C, Puglisi F, Olmeo N, Aitini E, Colucci G. et al. A multicentre phase II study of non-pegylated liposomal doxorubcin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast 2010; 10: 333-338.
• 25 Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff ALRosenzweig. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
• 26 Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA. et al. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J Clin Oncol 2012; 30: 1796-1604.
• 27 Von Minckwitz G, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P. et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). ASCO 2013. Oral Presentation, abstr 1004, Available at: URL: http://meetinglibrary.asco.org